Open AccessPropofol activates AMPK to inhibit the growth of HepG2 cells in vitro and hepatocarcinogenesis in xenograft mouse tumor models by inducing autophagy
Author(s) -
Yixiong Wang,
Baozhu Xu,
Jianying Zhou,
Xianyan Wu
Publication year - 2020
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-20-472
Subject(s) - survivin , apoptosis , proliferating cell nuclear antigen , ampk , cell cycle , flow cytometry , viability assay , medicine , cell growth , cancer research , cyclin d1 , cell , microbiology and biotechnology , protein kinase a , kinase , biology , pathology , immunology , immunohistochemistry , biochemistry
Hepatocellular carcinoma (HCC) is a fatal malignant tumor with a poor prognosis, and is the third leading cause of cancer-related deaths worldwide. This study aimed to investigate the anti-tumor effect of propofol on the proliferation, apoptosis, and cell cycle of HCC by regulating adenosine monophosphate-activated protein kinase (AMPK) in vivo and in vitro .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom